The Endocrine Center

05/01/2026

04/29/2026

The American Diabetes Association (ADA) recommends applying obesity management strategies used in the general adult population, including GLP-1 RA–based therapy, to adults with type 1 diabetes who have obesity (BMI ≥30.0 kg/m², or ≥27.5 kg/m² in Asian American individuals), with shared decision-making to inform individualized care.

No GLP-1 RA is currently FDA-approved specifically for type 1 diabetes. However, the ADA 2026 Standards of Care acknowledge growing real-world use — approximately 6.5% of people with type 1 diabetes were prescribed GLP-1 RAs or dual GIP/GLP-1 RAs in 2023.

Small retrospective case series and pilot studies suggest potential benefits with semaglutide and tirzepatide for individuals with type 1 diabetes and obesity, and prospective trials evaluating cardiovascular and kidney outcomes are ongoing.

Stay connected for updates you won’t hear everywhere else! 💜

04/29/2026

…
The 2026 ACC/AHA Dyslipidemia Guidelines recommend measuring Lp(a) at least once in all adults, ideally with the first lipid profile.

A single measurement is generally sufficient since levels are predominantly genetically determined and remain stable over a lifetime.

Fasting is not required.

Secondary causes of elevated Lp(a) include kidney, liver, or thyroid disease; pregnancy; and menopause.
Testing first-degree relatives is recommended when high Lp(a) is identified, particularly with a personal or family history of premature ASCVD.

- Lifestyle changes (smoking cessation, diet, exercise) do not meaningfully lower Lp(a) itself but are associated with a 67% lower ASCVD risk even among those with elevated Lp(a).
- Statins do not lower Lp(a) (and may modestly increase it by ~1 mg/dL), but remain essential for LDL-C reduction and overall cardiovascular benefit.
In the JUPITER trial, high-intensity statin therapy reduced events by 30–40% in individuals with elevated Lp(a).
- PCSK9 inhibitors (evolocumab, alirocumab, inclisiran) lower Lp(a) by approximately 15–30% in addition to substantial LDL-C lowering. Post hoc analyses from FOURIER and ODYSSEY Outcomes suggest patients with higher Lp(a) may derive greater benefit.
PCSK9 inhibitors should be preferentially considered in high-risk ASCVD patients with elevated Lp(a) who have not reached LDL-C goals.
- Lipoprotein apheresis is FDA-approved for Lp(a) ≥60 mg/dL in patients with FH and CAD or PAD, acutely lowering Lp(a) by 50–85% per session.

#

04/27/2026

The GLP-1 conversation is moving from injections… to pills. Meet orforglipron, an oral GLP-1 being studied for weight and diabetes. Stop guessing. Start feeling better.

Call us to discuss what weight loss treatment options are right for you! 💜

04/24/2026

… Kuddos to Roro for the idea 💡🙌🏻

We are board certified endocrinologists
We are more than capable of:
* Interpret labs in context (not just “normal vs abnormal”)
* Understand patterns over time, not just one snapshot
* Overview hormones safely and evidence-based
* Help patients navigate symptoms that don’t always fit neatly in a box
* Push back against misinformation (a lot of it)

Be careful out there…

04/18/2026

…There’s something humbling about becoming the patient when you’re used to being the physician.

You understand the system… but you also feel the vulnerability.

You know the guidelines…but suddenly, it’s personal.

You tell your patients to prioritize their health…
yet somehow, yours ends up last on the list.

Being on the other side is a reminder:
Medicine isn’t just science—it’s human.

And sometimes the best doctors… are the ones who remember what it feels like to sit in the patient chair